Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
$28.35
+0.3%		$32.09
$7.45
▼
$42.14
$730.51M-0.29431,223 shs187,921 shs
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
$64.51
+1.4%		$75.17
$1.16
▼
$14.10
$2.80B-0.12189,291 shs684,730 shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$23.20
-4.0%		$25.56
$21.02
▼
$42.21
$2.89B0.11.91 million shs1.55 million shs
Precigen, Inc. stock logo
PGEN
Precigen
$8.54
+4.0%		$7.06
$2.99
▼
$8.98
$2.93B0.924.75 million shs6.36 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
+0.28%+1.25%-27.53%+23.69%+2,834,999,900.00%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
-2.83%-4.26%-19.14%-16.59%-3.74%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-3.97%+2.75%-9.34%-33.39%-20.98%
Precigen, Inc. stock logo
PGEN
Precigen
+4.02%+10.19%+21.83%+51.42%+155.69%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
$28.35
+0.3%		$32.09
$7.45
▼
$42.14
$730.51M-0.29431,223 shs187,921 shs
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
$64.51
+1.4%		$75.17
$1.16
▼
$14.10
$2.80B-0.12189,291 shs684,730 shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$23.20
-4.0%		$25.56
$21.02
▼
$42.21
$2.89B0.11.91 million shs1.55 million shs
Precigen, Inc. stock logo
PGEN
Precigen
$8.54
+4.0%		$7.06
$2.99
▼
$8.98
$2.93B0.924.75 million shs6.36 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
+0.28%+1.25%-27.53%+23.69%+2,834,999,900.00%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
-2.83%-4.26%-19.14%-16.59%-3.74%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-3.97%+2.75%-9.34%-33.39%-20.98%
Precigen, Inc. stock logo
PGEN
Precigen
+4.02%+10.19%+21.83%+51.42%+155.69%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
2.93
Moderate Buy$56.2598.41% Upside
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
0.00
N/AN/AN/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
2.85
Moderate Buy$49.73114.34% Upside
Precigen, Inc. stock logo
PGEN
Precigen
2.83
Moderate Buy$13.6760.03% Upside

Current Analyst Ratings Breakdown

Latest FTH, NAMS, GMTX, and PGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/25/2026
Precigen, Inc. stock logo
PGEN
Precigen
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$12.00
9/24/2026
Precigen, Inc. stock logo
PGEN
Precigen
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$12.00
9/16/2026
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$70.00
9/15/2026
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
9/14/2026
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/9/2026
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy
9/8/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$52.00
8/21/2026
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$56.00
8/11/2026
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$60.00
8/6/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$51.00 ➝ $50.00
8/5/2026
Precigen, Inc. stock logo
PGEN
Precigen
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$14.00 ➝ $18.00
(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
N/AN/AN/AN/A$14.74 per shareN/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/A$2.89 per shareN/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$22.50M123.26N/AN/A$5.97 per share3.89
Precigen, Inc. stock logo
PGEN
Precigen
$9.68M314.52N/AN/A$0.06 per share142.33
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
-$21.08M-$141.65N/AN/AN/AN/A-1,012.17%-175.69%N/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$203.82M-$2.16N/AN/AN/A-3,644.21%-34.81%-31.50%11/4/2026 (Estimated)
Precigen, Inc. stock logo
PGEN
Precigen
-$250.64M-$1.04N/A11.70N/A-183.98%423.75%84.39%11/12/2026 (Estimated)

Latest FTH, NAMS, GMTX, and PGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$0.4819-$0.52-$0.0381-$0.52$2.83 million$3.70 million
8/4/2026Q2 2026
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
-$5.0450-$2.84+$2.2050-$0.62N/AN/A
8/4/2026Q2 2026
Precigen, Inc. stock logo
PGEN
Precigen
-$0.0121$0.05+$0.0621$0.05$27.98 million$54.98 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
N/AN/AN/AN/AN/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/AN/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/AN/AN/AN/AN/A
Precigen, Inc. stock logo
PGEN
Precigen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
N/A
19.69
19.69
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/A
71.49
71.49
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/A
9.03
9.03
Precigen, Inc. stock logo
PGEN
Precigen
2.15
4.58
3.89

Institutional Ownership

CompanyInstitutional Ownership
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
10.50%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
75.42%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
89.89%
Precigen, Inc. stock logo
PGEN
Precigen
33.51%

Insider Ownership

CompanyInsider Ownership
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
7.00%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
12.90%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
12.74%
Precigen, Inc. stock logo
PGEN
Precigen
41.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
2925.84 million24.03 millionNot Optionable
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
3043.33 million37.74 millionNot Optionable
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
100119.54 million104.31 millionOptionable
Precigen, Inc. stock logo
PGEN
Precigen
47356.51 million208.92 millionOptionable

Recent News About These Companies

4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
October 2 at 9:01 AM  |  zacks.comhttps://www.zacks.com/stock/news/2999327/4-low-beta-healthcare-stocks-to-buy-amid-fears-of-another-rate-hike?cid=cs-stocknewsapi-ft-analyst_blog|investment_ideas-2999327
Precigen (NASDAQ:PGEN) Reaches New 52-Week High - Should You Buy?
October 2 at 7:21 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31078658
Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?
October 1 at 5:36 AM  |  zacks.comhttps://www.zacks.com/stock/news/2998591/precigen-pgen-soars-6-3-is-further-upside-left-in-the-stock?cid=cs-stocknewsapi-ft-fundamental_analysis|daily_price_change_5%-2998591
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
September 30 at 1:11 PM  |  zacks.comhttps://www.zacks.com/stock/news/2998371/pgen-vs-irwd-which-biotech-stock-offers-better-growth-potential?cid=cs-stocknewsapi-ft-analyst_blog|most_popular_stocks-2998371
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
September 30 at 1:04 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/pgen-vs-irwd-biotech-stock-150800736.html
Precigen: The FDA's Platform Technology Designation And The Institutional Crossover Effect
September 30 at 1:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4951004-precigen-the-fdas-platform-technology-designation-and-the-institutional-crossover-effect
Precigen (NASDAQ:PGEN) Hits New 12-Month High - Here's What Happened
September 30 at 12:19 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-precigen-nasdaq-pgen-hits-new-12-month-high-heres-what-happened-2026-09-30/
Head to Head Contrast: Emergent Biosolutions (NYSE:EBS) vs. Precigen (NASDAQ:PGEN)
September 30 at 4:58 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31068357
Critical Review: TScan Therapeutics (NASDAQ:TCRX) vs. Precigen (NASDAQ:PGEN)
September 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31063385
Precigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs?
September 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/precigen-pgen-gets-fda-recognition-015839357.html
Precigen (NASDAQ:PGEN) Shares Gap Up After Analyst Upgrade
September 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31054493
Bank of America Corp DE Buys 1,848,414 Shares of Precigen, Inc. $PGEN
September 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-buys-1848414-shares-of-precigen-inc-pgen-2026-09-27/
Precigen (PGEN) Gains FDA Platform Backing, Is The Stock Still Cheap?
September 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/precigen-pgen-gains-fda-platform-170940636.html
B Riley Securities initiates coverage of Precigen at buy
September 26, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/b-riley-securities-initiates-coverage-of-precigen-at-buy/ar-AA2cZ9VI
B. Riley Financial Upgrades Precigen (NASDAQ:PGEN) to "Strong-Buy"
September 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-b-riley-financial-upgrades-precigen-nasdaq-pgen-to-strong-buy-2026-09-26/
Precigen (PGEN) Secures FDA Platform Status For AdenoVerse And Future Therapies
September 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/precigen-pgen-secures-fda-platform-161139077.html
Precigen (NASDAQ:PGEN) Shares Gap Up - Here's What Happened
September 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-precigen-nasdaq-pgen-shares-gap-up-heres-what-happened-2026-09-25/
Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?
September 24, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2995241/can-pgen-s-adenoverse-pipeline-create-growth-beyond-papzimeos?cid=cs-stocknewsapi-ft-analyst_blog|quick_take-2995241
Corient Private Wealth LP Sells 577,406 Shares of Precigen, Inc. $PGEN
September 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-corient-private-wealth-lp-sells-577406-shares-of-precigen-inc-pgen-2026-09-24/
Precigen (NASDAQ:PGEN) Hits New 12-Month High - What's Next?
September 23, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31042211
Precigen (NASDAQ:PGEN) Hits New 1-Year High - Time to Buy?
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-precigen-nasdaq-pgen-hits-new-1-year-high-time-to-buy-2026-09-23/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Sensei Biotherapeutics stock logo

Sensei Biotherapeutics NASDAQ:FTH

$28.35 +0.08 (+0.28%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$28.38 +0.04 (+0.12%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Gemini Therapeutics stock logo

Gemini Therapeutics NASDAQ:GMTX

$64.51 +0.90 (+1.41%)
As of 10/2/2026

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

NewAmsterdam Pharma stock logo

NewAmsterdam Pharma NASDAQ:NAMS

$23.20 -0.96 (-3.97%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$23.72 +0.53 (+2.26%)
As of 10/2/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Precigen stock logo

Precigen NASDAQ:PGEN

$8.54 +0.33 (+4.02%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$8.55 +0.01 (+0.12%)
As of 10/2/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas